The EU Court of Justice rules that the dissemination of misleading information is a restriction by object and excludes exemption under Article 101 §3 TFEU (Roche / Novartis)

On 23 January 2018, the Court of Justice of the European Union delivered its decision on the preliminary ruling referred to it by the Italian Council of State in the dispute between Roche and Novartis on the one hand and the Italian competition authority (AGCM) on the other. In 2014, Roche and Novartis were each fined more than €90m for entering into an agreement "to achieve an artificial differentiation between the medicinal products Avastin and Lucentis by manipulating the perception of the risks of using Avastin in the field of ophthalmology". Avastin and Lucentis are two medicinal products belonging to the Roche group. Avastin has been commercialised by Roche itself as an oncological medicinal product while the commercialisation of Lucentis as an ophthalmic medicinal product has

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Floriane Aufaure, Ombline Ancelin, The EU Court of Justice rules that the dissemination of misleading information is a restriction by object and excludes exemption under Article 101 §3 TFEU (Roche / Novartis), 23 January 2018, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 86139

Visites 1303

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues